Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
5.290
+0.050 (+0.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exscientia Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
February 02, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
December 06, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
November 28, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Business and Financial Update for the Third Quarter 2022
November 15, 2022
From
Exscientia plc
Via
Business Wire
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
November 14, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
November 08, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Expands Biologics Design Capability with Automated Laboratory
November 03, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in November
November 01, 2022
From
Exscientia
Via
Business Wire
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
October 28, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
October 26, 2022
From
Exscientia plc
Via
Business Wire
Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
September 20, 2022
From
Exscientia
Via
Business Wire
Exscientia Welcomes Caroline Rowland as Chief People Officer
September 08, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in September
September 07, 2022
From
Exscientia
Via
Business Wire
Exscientia Business Update for Second Quarter and First Half 2022
August 17, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022
August 10, 2022
From
Exscientia
Via
Business Wire
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
June 14, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022
From
Exscientia
Via
Business Wire
Exscientia Business Update for First Quarter 2022
May 25, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Report First Quarter 2022 Financial Results on May 25, 2022
May 18, 2022
From
Exscientia
Via
Business Wire
Exscientia to Present at the BofA Securities 2022 Healthcare Conference
May 03, 2022
From
Exscientia
Via
Business Wire
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
April 08, 2022
From
Exscientia plc
Via
Business Wire
Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
April 05, 2022
From
Exscientia
Via
Business Wire
Exscientia Business Update for Fourth Quarter and Full Year 2021
March 23, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022
March 16, 2022
From
Exscientia
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
February 22, 2022
From
Exscientia
Via
Business Wire
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
January 19, 2022
From
Exscientia
Via
Business Wire
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
January 07, 2022
From
Exscientia
Via
Business Wire
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
November 23, 2021
From
Exscientia
Via
Business Wire
Exscientia Business Update for Third Quarter 2021
November 17, 2021
From
Exscientia
Via
Business Wire
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
November 10, 2021
From
Exscientia
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.